CN107510813A - 用于降低癌症治疗药物副作用的医药组合物、制备方法及其用途 - Google Patents
用于降低癌症治疗药物副作用的医药组合物、制备方法及其用途 Download PDFInfo
- Publication number
- CN107510813A CN107510813A CN201610614678.8A CN201610614678A CN107510813A CN 107510813 A CN107510813 A CN 107510813A CN 201610614678 A CN201610614678 A CN 201610614678A CN 107510813 A CN107510813 A CN 107510813A
- Authority
- CN
- China
- Prior art keywords
- grams
- medical composition
- class
- cancer
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 55
- 201000011510 cancer Diseases 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims abstract description 20
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 14
- 210000004185 liver Anatomy 0.000 claims abstract description 14
- 241000195493 Cryptophyta Species 0.000 claims abstract description 10
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 210000000056 organ Anatomy 0.000 claims abstract description 7
- 230000005784 autoimmunity Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 61
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 19
- 229960002949 fluorouracil Drugs 0.000 claims description 16
- 229930012538 Paclitaxel Natural products 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 229960001592 paclitaxel Drugs 0.000 claims description 14
- 235000002639 sodium chloride Nutrition 0.000 claims description 14
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 13
- 208000002193 Pain Diseases 0.000 claims description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000036407 pain Effects 0.000 claims description 11
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 9
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 240000002853 Nelumbo nucifera Species 0.000 claims description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 7
- 229960004316 cisplatin Drugs 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 241001131796 Botaurus stellaris Species 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- 229920002101 Chitin Polymers 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 229940000425 combination drug Drugs 0.000 claims description 5
- 229960003180 glutathione Drugs 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 235000010204 pine bark Nutrition 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 241000205585 Aquilegia canadensis Species 0.000 claims description 4
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 4
- 241000132012 Atractylodes Species 0.000 claims description 4
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 4
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 4
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 4
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 4
- 244000077995 Coix lacryma jobi Species 0.000 claims description 4
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims description 4
- 241000208688 Eucommia Species 0.000 claims description 4
- 240000008397 Ganoderma lucidum Species 0.000 claims description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 241000830535 Ligustrum lucidum Species 0.000 claims description 4
- 240000001659 Oldenlandia diffusa Species 0.000 claims description 4
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 4
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 4
- 240000007594 Oryza sativa Species 0.000 claims description 4
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- 241000123107 Phellinus Species 0.000 claims description 4
- 241001165494 Rhodiola Species 0.000 claims description 4
- 240000007164 Salvia officinalis Species 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 4
- 244000300264 Spinacia oleracea Species 0.000 claims description 4
- 241001486992 Taiwanofungus camphoratus Species 0.000 claims description 4
- 244000185386 Thladiantha grosvenorii Species 0.000 claims description 4
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 4
- 241000218989 Trichosanthes Species 0.000 claims description 4
- 240000008042 Zea mays Species 0.000 claims description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000005822 corn Nutrition 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 230000035784 germination Effects 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000005412 red sage Nutrition 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 240000006079 Schisandra chinensis Species 0.000 claims description 3
- 241001593968 Vitis palmata Species 0.000 claims description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 3
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 235000004634 cranberry Nutrition 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 1
- 244000042664 Matricaria chamomilla Species 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 abstract description 3
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 16
- 206010009944 Colon cancer Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 201000005249 lung adenocarcinoma Diseases 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 235000011147 magnesium chloride Nutrition 0.000 description 3
- 240000003538 Chamaemelum nobile Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 240000007332 Podocarpus macrophyllus Species 0.000 description 1
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种用于降低癌症治疗药物副作用的医药组合物,包括菇类、根茎类、果实种子类、叶类、花类、藻类、能量配置液、盐类配置液、补助剂以及抗氧化剂。所述医药组合物具有保护肝脏、提升自体免疫力、减缓癌痛、保护器官免于癌症治疗药物所造成的副作用或提升该化学治疗癌症药物治疗癌症的功效。
Description
技术领域
本发明是关于一种癌症用药,特别是一种可合并化疗治疗癌症药物使用的癌症用药。
背景技术
化学治疗是癌症患者重要的一个治疗方法,其是透过给予患者抗癌药物,以杀死体内的癌细胞。相较于传统的手术治疗和放射线治疗,化学治疗的优点是达到全身性的治疗,因此为目前最主要的癌症治疗方式,亦是转移性癌症患者最重要的治疗方式。
目前市售的化学治疗药物,可分为化合药物和标靶药物。化合药物包括扑类恶注射剂(Bleomycin)、顺铂(Cisplatin)、5-氟尿嘧啶(Fluorouracil,5-FU)、灭杀除癌锭(Methotrexate)、紫杉醇(Taxol)等,其作用机制是攻击***快速的细胞,因此除癌细胞外,人体正常细胞包括白血球、红血球、血小板、头发毛囊细胞、胃肠道表皮细胞、生殖细胞等等皆成为化学治疗药物的作用对象,导致患者服用后常伴随着如恶心呕吐、出血、腹泻、白血球过低而导致容易感染、落发、口腔或食道黏膜破损发炎、生育功能降低等等的副作用。
标靶药物,包括癌思停(Bevacizumab)、爱瑞莎(Iressa)以及得舒缓(Erlotinib)等,其作用机制是针对癌细胞上特有的抗原、蛋白等进行标靶治疗,因此仅能针对原发部位的癌细胞给予治疗,对于转移性癌症患者并没有效果,此外,标靶药物亦会有皮肤红疹、手足疼痛、口腔炎、腹泻、肠胃不适、发烧、肌肉酸痛、血压升高、肝功能受损等副作用产生。
另外,有些化学治疗药物,如Fluorouracil(5-FU)、Taxol(紫杉醇),更会引起患者心律不整、肝肾功能下降、疼痛、器官肥大等等,因而严重影响癌症患者的生活质量。因此,目前仍需要一种可以降低化学治疗药物副作用并提升其治疗功效的药物,用于合并治疗癌症。
发明内容
有鉴于此,本发明提供一种可合并化学治疗药物使用,并可用于降低癌症治疗药物副作用的医药组合物,包括菇类、根茎类、果实种子类、叶类、花类、藻类、能量配置液、盐类配置液、补助剂以及抗氧化剂。
本发明之一实施例中,所述菇类是选自桑黄24-36克、灵芝16-24克、巴西蘑菇16-24克、牛樟芝4-6克、冬虫夏草4-6克中的一种或多种。
本发明之一实施例中,所述根茎类是选自黄精16-24克、黄芪8-12克、丹参8-12克、党参8-12克、白花蛇舌草12-18克、杜仲12-18克、白术8-12克、天花粉8-12克、刺五加8-12克、麦冬8-12克、红景天8-12克、去皮甘草2.4-3.6克中的一种或多种。
本发明之一实施例中,所述果实种子类是选自薏仁12-18克、女贞子8-12克、五味子8-12克、发芽米9.6-14.4克、莲子8-12克、黑芝麻8-12克、玉米须8-12克、罗汉果8-12克、红葡萄皮萃取粉1.6-2.4克中的一种或多种。
本发明之一实施例中,所述叶类是选自菠菜8-12克、发芽青花菜8-12克、木瓜叶8-12克、荷叶6.4-9.6克中的一种或多种。
本发明之一实施例中,所述花类是选自贡菊8-12克、黄菊8-12克、金银花8-12克、洋甘菊8-12克中的一种或多种。
本发明之一实施例中,所述藻类是选自海藻8-12克、昆布8-12克、海带8-12克中的一种或多种。
本发明之一实施例中,所述能量配置液包含氯化铁4.5-5.5毫克以及蒸馏水200毫升。
本发明之一实施例中,所述盐类配置液包含深海盐112.5-137.5克、氯化镁27-33克、盐卤18-22毫升、氯化钙0.99-1.21克以及氯化钾0.495-0.605克。
本发明之一实施例中,所述补助剂包含柠檬酸18-22克、硒酵母18-22克、辅酶10270-330毫克或维生素C 2.7-3.3克。
本发明之一实施例中,所述抗氧化剂包含几丁质聚寡糖9-11克、谷胱甘肽4.5-5.5克、松树皮0.9-1.1克或褐藻多糖0.9-1.1克中的一种或多种。
本发明之一实施例中,所述医药组合物的pH值介于1.2-2之间。较佳地,所述医药组合物的pH值为1.2-1.8。
本发明另提供一种降低癌症治疗药物副作用的医药组合物的制备方法,包括:将中医原料加入水中,并浓缩成原料溶液;加入含有氯化铁(FeCl3)的水;加入含有深海盐、氯化镁、盐卤、氯化钙以及氯化钾的盐类配制液;加入含有柠檬酸、硒酵母、辅酶10以及维生素C的补助剂;加入含有几丁质聚寡糖、谷胱甘肽、松树皮以及褐藻多糖的抗氧化剂;混合后,进行发酵反应;以及进行离心步骤,以得到医药组合物。
本发明之一实施例中,所述中医原料包括菇类、根茎类、果实种子类、叶类、花类、藻类中的一种或多种。
本发明之一实施例中,所述菇类是选自桑黄24-36克、灵芝16-24克、巴西蘑菇16-24克、牛樟芝4-6克、冬虫夏草4-6克中的一种或多种,所述根茎类是选自黄精16-24克、黄芪8-12克、丹参8-12克、党参8-12克、白花蛇舌草12-18克、杜仲12-18克、白术8-12克、天花粉8-12克、刺五加8-12克、麦冬8-12克、红景天8-12克、去皮甘草2.4-3.6克中的一种或多种,所述果实种子类是选自薏仁12-18克、女贞子8-12克、五味子8-12克、发芽米9.6-14.4克、莲子8-12克、黑芝麻8-12克、玉米须8-12克、罗汉果8-12克、红葡萄皮萃取粉1.6-2.4克中的一种或多种,所述该叶类是选自菠菜8-12克、发芽青花菜8-12克、木瓜叶8-12克、荷叶6.4-9.6克中的一种或多种,所述花类是选自贡菊8-12克、黄菊8-12克、金银花8-12克、洋甘菊8-12克中的一种或多种,所述藻类是选自海藻8-12克、昆布8-12克、海带8-12克中的一种或多种。
本发明之一实施例中,所述医药组合物的pH值介于1.2-2之间。较佳地,所述癌症用药的pH值为1.2-1.8。
本发明之一实施例中,所述发酵反应是于常温下进行3-5天的发酵。
本发明进一步提供一种制备用于降低癌症治疗药物副作用的医药组合物的方法,所述医药组合物包含菇类、根茎类、果实种子类、叶类、花类、藻类、能量配置液、盐类配置液、补助剂以及抗氧化剂。
本发明之一实施例中,所述医药组合物具有保护肝脏、提升自体免疫力、减缓癌痛、保护器官免于癌症治疗药物所造成的副作用或提升所述癌症治疗药物治疗癌症的功效。
本发明之一实施例中,所述医药组合物的浓度为25μl/kg/day-84μl/kg/day。
本发明之一实施例中,所述医药组合物的使用方法为一日内分为3-10次使用,且每次使用时需将所述医药组合物稀释1/1000-3/1000倍后再使用。
本发明之一实施例中,所述癌症治疗药物包括化合药物或标靶药物。所述化合物包括5-氟尿嘧啶(5-FU)、紫杉醇(Taxol)、顺铂(cisplatin)、小红莓类(anthracycline)、环磷酰胺(cyclophosphamide)中的一种或多种。
本发明之一实施例中,所述器官为心脏、肝脏、肾脏或脾脏。
附图说明
图1A为各组公鼠于第14天时的肿瘤体积。
图1B为各组公鼠于第14天时抑制肿瘤体积的倍数变化图。
图2A为接肿大肠癌细胞后,各组公鼠血清中丙氨酸转氨酶(Alanine aminotransferase)的表达量。
图2B为接肿肺腺癌细胞后,各组公鼠血清中丙氨酸转氨酶(Alanine aminotransferase)的表达量。
图3为接肿大肠癌细胞后,各组公鼠血液中免疫细胞的数量,其中:
图3A为白血球的数量;图3B为淋巴细胞的数量;图3C为单核球的数量;图3D为颗粒性球的数量;图3E为血小板的数量。
图4为接肿肺腺癌细胞后,各组公鼠血液中免疫细胞的数量,其中:
图4A为白血球的数量;图4B为红血球的数量;图4C为单核球的数量;图4D为颗粒性球的数量;图4E为血小板的数量。
图5为接肿大肠癌细胞后,各组公鼠血液中细胞激素的表达量,其中:
图5A为人类细胞激素IL-8的表达量;图5B为人类细胞激素IL-6的表达量;图5C为人类细胞激素IL-1RA的表达量;图5D为人类细胞激素TNF-α的表达量;图5E为老鼠细胞激素G-CSF的表达量;图5F为老鼠细胞激素IL-12的表达量;图5G为人类细胞激素IL-12的表达量。
图6为接肿肺腺癌细胞后,各组公鼠血液中细胞激素的表达量,其中:
图6A为人类细胞激素IL-6的表达量;图6B为人类细胞激素TNF-α的表达量;图6C为老鼠细胞激素G-CSF的表达量;图6D为人类细胞激素IL-12的表达量。
7图为各组公鼠于不同天数引发疼痛的比较图。
图8为各组公鼠器官重量,其中:图8A为公鼠心脏重量;图8B为公鼠肝脏重量;图8C为公鼠脾脏重量;图8D为公鼠肾脏重量。
具体实施方式
实施例一、本发明医药组合物的制备
首先,将表1所述的一种或多种中医原料制备成浓缩液,该浓缩液的制备流程为:(1)取360克中医原料,并加入6倍的水,制成约2160毫升的溶液;(2)于高温(约70℃)环境下,将该溶液以减压方式浓缩成1200毫升;(3)将浓缩后的溶液冷藏静置,并于两天后去除5%沉淀物,已取得浓缩液。
表1、本发明医药组合物的原料
接着,取上述浓缩液200毫升(内含60克的固体量),依序加入能量配置液、盐类配置液、补助剂及抗氧化剂,混合搅拌后于常温(25℃)下进行发酵,发酵时间约3-7天,较佳为3天。其中,该能量配置液为含5毫克氯化铁(FeCl3)的蒸馏水200毫升,该盐类配制液包含125克深海盐、30克氯化镁、20毫升盐卤、1.1克氯化钙(CaCl2)以及0.55克氯化钾(KCL),该补助剂包含20克柠檬酸、20克硒酵母、300毫克(浓度10%)辅酶10(Q10)以及3克维生素C,该抗氧化剂包含10克(浓度70%)几丁质聚寡糖、5克(浓度98%)谷胱甘肽、1克(浓度80%)松树皮以及1克(浓度80%)褐藻多糖。
将上述发酵后的液体,加入蒸馏水使其总体积为500毫升,搅拌静置一天后,以1500rpm离心15分钟用以分离沉淀物,该上清液即为本发明的医药组合物,内含25%深海盐、6%氯化镁,且该医药组合物的pH值为1.5±0.3,以保持产品的安定。
实施例二、本发明医药组合物对肿瘤生长的影响
将7周龄大且体重20-24克的公鼠(CB17/Icr-Prkdcscid/IcrIcoCrlBltw),以皮下接种方式给予3×106HT-2大肠癌细胞(100μL PBS含50%基质胶(matrigel))或1×107A549肺腺癌细胞(100μL PBS含50%基质胶(matrigel)),使其诱发大肠癌或肺腺癌。待肿瘤体积生长到200mm3时,将公鼠分为以下三组:(一)控制组,于第0-14天皆不给予任何药物;(二)对照组,于第0、7天给予化疗药物5-FU(100mg/kg)或cisplatin(4mg/kg);以及(三)实验组,在给予5-FU或cisplatin之前7天就开始给予本发明医药组合物,并连续给予21天,每天给予2次,每次剂量为0.5-1.67μL/只(公鼠),其中在第0、7天给予化疗药物5-FU(100mg/kg)或cisplatin(4mg/kg)时不给予本发明医药组合物。于第14天给药后,取出肿瘤块测量其重量。
结果显示,如图1A、1B,与控制组相比,给予化疗药物5-FU的公鼠(即对照组),平均能减少6.3%的肿瘤体积,其抑制效果为控制组的1倍,然而,合并给予化疗药物5-FU及本发明医药组合物的公鼠(即实验组),能有效减少34.1%的肿瘤体积,其抑制效果为控制组的5.4倍,有此可知,本发明医药组合物具有促进化疗药物5-FU抑制肿瘤的效果。
实施例三、本发明医药组合物对肝脏功能的影响
许多研究已证实,癌细胞会经血流进入肝脏,进而影响肝功能。因此,将上述实施例二的各组公鼠,于第14天给药后,采集各组公鼠的血清,用以分析其肝指数丙氨酸转氨酶(Alanine amino transferase,ALT)的表达量。
参考图2A,图中正常鼠为没有接踵大肠癌细胞,亦不给予任何药物。结果显示,与正常鼠相比,控制组中公鼠血清的ALT浓度增加,表示大肠癌细胞确实造成公鼠肝脏受损。而与控制组相比,对照组的ALT浓度增加,而实验组的ALT浓度降低至与正常鼠的ALT相近。
如图2B,图中正常鼠为没有接踵肺腺癌细胞,亦不给予任何药物。结果显示,与正常鼠、控制组相比,对照组的ALT浓度增加,而实验组的ALT浓度降低至与正常鼠的ALT相近。由以上结果可知,化疗药物5-FU及Cisplatin不具有保护肝脏免于癌细胞破坏的功效,反而是增加肝脏负担,并加速肝脏受损,然而本发明医药组合物具有保护肝脏作用,并使其维持正常的肝功能状态,以增加对抗癌细胞的功效。
实施例四、本发明医药组合物对免疫***的影响
已知免疫细胞、细胞激素在抑制恶性肿瘤的生长上扮演着一个重要的角色,为了了解本发明医药组合物对于免疫细胞的影响,将上述实施例二的各组公鼠,于第14天给药后,采集各组公鼠的血液,用以分析免疫细胞、细胞激素的表达量。
如图3A-3E所示,图中正常鼠为没有接踵大肠癌细胞,亦不给予任何药物。结果显示,与控制组、对照组相比,本发明医药组合物能有效提升血液中白血球(white bloodcell)(图3A)、淋巴细胞(lymphocytes)(图3B)、单核球(monocytes)(图3C)、颗粒性球(granulocytes)(图3D)以及血小板(platelet)(图3E)的数量。
如图4A-4E所示,图中正常鼠为没有接踵肺线癌细胞,亦不给予任何药物。结果显示,与控制组、对照组相比,本发明医药组合物能有效提升血液中白血球(white bloodcell)(图4A)、红血球(Red blood cell)(图4B)、单核球(monocytes)(图4C)、颗粒性球(granulocytes)(图4D)以及血小板(platelet)(图4E)的数量。
如图5A-5G所示,图中正常鼠为没有接踵大肠癌细胞,亦不给予任何药物。结果显示,与控制组、对照组相比,本发明医药组合物能减少人类细胞激素IL-8(图5A)、IL-6(图5B)、IL-1RA(图5C)、TNF-α(图5D)的表现,并增加老鼠细胞激素G-CSF(血球生长激素)(图5E)、IL-12(p70)(图5F)的表达以及增加人类IL-12(p70)(图5G)的表达。
如图6A-6D所示,图中正常鼠为没有接踵肺腺癌细胞,亦不给予任何药物。结果显示,与控制组、对照组相比,本发明医药组合物能减少人类细胞激素IL-6(图6A)、TNF-α(图6B)的表达,并增加老鼠细胞激素G-CSF(血球生长激素)(图6C)以及增加人类IL-12(p70)(图6D)的表达。综合以上结果可知,本发明医药组合物有助于癌症患者提升自体免疫力。
实施例五、本发明医药组合物对癌痛的影响
癌痛为癌症引起的疼痛,是癌症患者最常见的症状之一,也是癌症患者最畏惧的症状之一,若没有适当的控制疼痛,往往严重影响癌症患者的生活质量。因此,为了解本发明医药组合物对癌痛的影响,将6-7龄大且体重20-24克的雌鼠(ICR)分为控制组、对照组及实验组这三组,其中控制组为没有给予任何药物,对照组与实验组皆为第0-5天连续给予癌痛指标药物紫杉醇(20mg/kg),藉此诱发雌鼠产生疼痛作用,而实验组在给予紫杉醇(Taxol)之前7天就开始给予本发明医药组合物,并连续给予21天,每天给予2次,每次剂量为0.5-1.67uL/只(雌鼠)。接着,于给药期间第3、7、14天,分别进行闪尾痛觉测试(Tail-Flick Unit 37360),该测试是以红外线热源对雌鼠尾部加热,用以分析闪尾延迟秒数(tail flick latency/sec),藉此评估痛觉阈值改变的程度。
如图7所示,图中对照组的闪尾秒数较少,表示紫杉醇(Taxol)确实会导致老鼠的疼痛敏感度增加,然而与对照组相比,不论是第3、7及14天,实验组皆有延长闪尾秒数,表示本发明医药组合物具有减缓癌痛的功效。
实施例六、本发明医药组合物对各器官的影响
化疗药物常见的副作用是造成器官肥大,因此为了解本发明医药组合物对于各器官的影响,本试验将上述实施例五的雌鼠,于第15天后牺牲,分别取心脏、肝脏、脾脏及肾脏并秤重。
如他8A-8D所示,与控制组相比,给予紫杉醇(Taxol)的雌鼠(即对照组),其心脏(图8A)、肝脏(图8B)、脾脏(图8C)及肾脏(图8D)都明显较重。然而在实验组的雌鼠,其心脏(图8A)、肝脏(图8B)、脾脏(图8C)及肾脏(图8D)的重量皆明显降低,甚至比控制组低。由此可知,本发明医药组合物具有保护器官免于化疗药物造成的副作用。
Claims (23)
1.一种用于降低癌症治疗药物副作用的医药组合物,包括菇类、根茎类、果实种子类、叶类、花类、藻类、能量配置液、盐类配置液、补助剂以及抗氧化剂。
2.如权利要求1所述医药组合物,其特征是,所述菇类是选自桑黄24-36克、灵芝16-24克、巴西蘑菇16-24克、牛樟芝4-6克、冬虫夏草4-6克中的一种或多种。
3.如权利要求1所述医药组合物,其特征是,所述根茎类是选自由黄精16-24克、黄芪8-12克、丹参8-12克、党参8-12克、白花蛇舌草12-18克、杜仲12-18克、白术8-12克、天花粉8-12克、刺五加8-12克、麦冬8-12克、红景天8-12克、去皮甘草2.4-3.6克中的一种或多种。
4.如权利要求1所述医药组合物,其特征是,所述果实种子类是选自薏仁12-18克、女贞子8-12克、五味子8-12克、发芽米9.6-14.4克、莲子8-12克、黑芝麻8-12克、玉米须8-12克、罗汉果8-12克、红葡萄皮萃取粉1.6-2.4克中的一种或多种。
5.如权利要求1所述医药组合物,其特征是,所述叶类是选自菠菜8-12克、发芽青花菜8-12克、木瓜叶8-12克和荷叶6.4-9.6克。
6.如权利要求1所述医药组合物,其特征是,所述花类是选自贡菊8-12克、黄菊8-12克、金银花8-12克或洋甘菊8-12克中的一种或多种。
7.如权利要求1所述医药组合物,其特征是,所述藻类是选自海藻8-12克、昆布8-12克或海带8-12克中的一种或多种。
8.如权利要求1所述医药组合物,其特征是,所述能量配置液包含氯化铁4.5-5.5毫克以及蒸馏水200毫升。
9.如权利要求1所述医药组合物,其特征是,所述盐类配置液包含深海盐112.5-137.5克、氯化镁27-33克、盐卤18-22毫升、氯化钙0.99-1.21克以及氯化钾0.495-0.605克。
10.如权利要求1所述医药组合物,其特征是,所述补助剂包含柠檬酸18-22克、硒酵母18-22克、辅酶10 270-330毫克以及维生素C2.7-3.3克。
11.如权利要求1所述医药组合物,其特征是,所述抗氧化剂包含几丁质聚寡糖9-11克、谷胱甘肽4.5-5.5克、松树皮0.9-1.1克以及褐藻多糖0.9-1.1克。
12.如权利要求1所述医药组合物,其特征是,所述医药组合物的pH值介于1.2-2之间。
13.一种降低癌症治疗药物副作用的医药组合物的制备方法,包括:
将中医原料加入水中,并浓缩成原料溶液;
加入含有氯化铁(FeCl3)的水;
加入含有深海盐、氯化镁、盐卤、氯化钙以及氯化钾的盐类配制液;
加入含有柠檬酸、硒酵母、辅酶10以及维生素C的补助剂;
加入含有几丁质聚寡糖、谷胱甘肽、松树皮以及褐藻多糖的抗氧化剂;
混合后,进行发酵反应;以及
进行离心步骤,以得到医药组合物,
其中所述医药组合物的pH值介于1.2-2之间。
14.如权利要求13所述方法,其特征是,所述中医原料包括菇类、根茎类、果实种子类、叶类、花类、藻类中的一种或多种。
15.如权利要求14所述方法,其特征是,所述菇类是选自桑黄24-36克、灵芝16-24克、巴西蘑菇16-24克、牛樟芝4-6克、冬虫夏草4-6克中的一种或多种,所述根茎类是选自黄精16-24克、黄芪8-12克、丹参8-12克、党参8-12克、白花蛇舌草12-18克、杜仲12-18克、白术8-12克、天花粉8-12克、刺五加8-12克、麦冬8-12克、红景天8-12克、去皮甘草2.4-3.6克中的一种或多种,所述果实种子类是选自薏仁12-18克、女贞子8-12克、五味子8-12克、发芽米9.6-14.4克、莲子8-12克、黑芝麻8-12克、玉米须8-12克、罗汉果8-12克、红葡萄皮萃取粉1.6-2.4克中的一种或多种,所述叶类是选自菠菜8-12克、发芽青花菜8-12克、木瓜叶8-12克、荷叶6.4-9.6克中的一种或多种,所述花类是选自贡菊8-12克、黄菊8-12克、金银花8-12克、洋甘菊8-12克中的一种或多种,所述藻类是选自海藻8-12克、昆布8-12克、海带8-12克中的一种或多种。
16.如权利要求13所述方法,其特征是,所述发酵反应是在常温下进行3-5天的发酵。
17.一种制备用于降低癌症治疗药物副作用的医药组合物的方法,其特征是,所述医药组合物如权利要求1所述,所述医药组合物具有保护器官免于癌症治疗药物所造成的副作用的功效。
18.如权利要求17所述方法,其特征是,所述医药组合物的浓度为25μl/kg/day-84μl/kg/day。
19.如权利要求17所述方法,其特征是,所述医药组合物的使用方法为一日内分为3-10次使用,且每次使用时须将所述医药组合物稀释1/1000-3/1000倍后再使用。
20.如权利要求17所述方法,其特征是,所述癌症治疗药物为化合药物或标靶药物。
21.如权利要求17所述方法,其特征是,所述化合药物包括5-氟尿嘧啶(5-FU)、紫杉醇(Taxol)、顺铂(cisplatin)、小红莓类(anthracycline)、环磷酰胺(cyclophosphamide)中的一种或多种。
22.如权利要求17所述方法,其特征是,所述医药组合物具有保护肝脏、提升自体免疫力、减缓癌痛、或提升该癌症治疗药物治疗癌症的功效。
23.如权利要求17所述方法,其特征是,所述器官为心脏、肝脏、肾脏或脾脏。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW105118779 | 2016-06-15 | ||
TW105118779 | 2016-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107510813A true CN107510813A (zh) | 2017-12-26 |
Family
ID=56888963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610614678.8A Pending CN107510813A (zh) | 2016-06-15 | 2016-07-29 | 用于降低癌症治疗药物副作用的医药组合物、制备方法及其用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11065293B2 (zh) |
EP (1) | EP3257517A1 (zh) |
CN (1) | CN107510813A (zh) |
TW (1) | TWI646964B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114642689A (zh) * | 2022-04-15 | 2022-06-21 | 深圳德荫堂生物科技有限公司 | 一种护肝醒酒的药物及生产方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11224607B2 (en) * | 2019-12-13 | 2022-01-18 | Deyu Sun | Anticancer composition of traditional Chinese medicine and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103656198A (zh) * | 2013-12-17 | 2014-03-26 | 青岛中科菲力工程技术研发有限公司 | 一种抗疲劳中药组合物 |
CN104415298A (zh) * | 2013-09-06 | 2015-03-18 | 中天生物科技股份有限公司 | 用于制造供化疗癌症患者使用的辅助治疗剂的组合物 |
CN104800573A (zh) * | 2015-05-06 | 2015-07-29 | 李桂香 | 一种治疗肝癌的中药组合物及其制备方法 |
CN104839651A (zh) * | 2015-04-08 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 肺癌医学配方食品 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1201805C (zh) * | 2003-07-18 | 2005-05-18 | 江苏省中医药研究院 | 一种用于放化疗减毒增效的药物组合物及其制备方法 |
CN101352213A (zh) * | 2007-07-24 | 2009-01-28 | 曲芳 | 一种五色全营养米饭及制作方法 |
CN101199596A (zh) * | 2007-12-21 | 2008-06-18 | 北京中科雍和医药技术有限公司 | 一种减轻癌症放、化疗毒副作用的中药组合物及其制备方法 |
TWI484968B (zh) * | 2013-05-07 | 2015-05-21 | Univ Southern Taiwan Tech | 兼具輔助治療肺癌、降低肺部纖維化功效的桑黃合併抗癌藥之複合組成物 |
CN103404759A (zh) * | 2013-05-27 | 2013-11-27 | 胡安然 | 一种冠心病患者食用的特殊膳食 |
CN103460989A (zh) * | 2013-08-05 | 2013-12-25 | 滁州市南谯区大柳镇凤胜食用菌专业合作社 | 一种降压保健灵芝的栽培方法 |
CN103920097A (zh) * | 2014-04-29 | 2014-07-16 | 杨明 | 一种治疗慢性***炎的药物组合物 |
TWI598104B (zh) * | 2014-11-28 | 2017-09-11 | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
CN104839663A (zh) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 甲状腺癌医学配方食品 |
CN105288278A (zh) * | 2015-11-03 | 2016-02-03 | 李业明 | 一种抗肿瘤中药微生物发酵制剂及其制备方法与应用 |
-
2016
- 2016-07-29 CN CN201610614678.8A patent/CN107510813A/zh active Pending
- 2016-09-07 EP EP16187578.6A patent/EP3257517A1/en not_active Withdrawn
- 2016-10-05 US US15/285,846 patent/US11065293B2/en active Active
-
2017
- 2017-06-06 TW TW106118745A patent/TWI646964B/zh active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104415298A (zh) * | 2013-09-06 | 2015-03-18 | 中天生物科技股份有限公司 | 用于制造供化疗癌症患者使用的辅助治疗剂的组合物 |
JP2015051970A (ja) * | 2013-09-06 | 2015-03-19 | マイクロバイオ カンパニー, リミテッド | 化学療法を受けているがん患者向けのアジュバントを製造するための組成物 |
CN103656198A (zh) * | 2013-12-17 | 2014-03-26 | 青岛中科菲力工程技术研发有限公司 | 一种抗疲劳中药组合物 |
CN104839651A (zh) * | 2015-04-08 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 肺癌医学配方食品 |
CN104800573A (zh) * | 2015-05-06 | 2015-07-29 | 李桂香 | 一种治疗肝癌的中药组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
刘吉华: "《中药生物技术》", 31 October 2015, 中国医药科技出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114642689A (zh) * | 2022-04-15 | 2022-06-21 | 深圳德荫堂生物科技有限公司 | 一种护肝醒酒的药物及生产方法 |
Also Published As
Publication number | Publication date |
---|---|
TW201800099A (zh) | 2018-01-01 |
TWI646964B (zh) | 2019-01-11 |
US11065293B2 (en) | 2021-07-20 |
US20170360866A1 (en) | 2017-12-21 |
EP3257517A1 (en) | 2017-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104721593B (zh) | 鲜天麻冻干粉和制法 | |
CN103386078B (zh) | 一种中药组合物在制备治疗结肠癌药物中的应用 | |
CN101380346A (zh) | 一种***的中药组合物及其制作方法 | |
CN102793715A (zh) | 一种马尾藻多糖及其在制备肾脏损伤药物中的应用 | |
CN107510813A (zh) | 用于降低癌症治疗药物副作用的医药组合物、制备方法及其用途 | |
CN104686657A (zh) | 一种具有抗肿瘤功效的配方驴奶粉 | |
CN104940241B (zh) | 一种防治妇女更年期综合征的硒虫草复方制剂 | |
CN106176787B (zh) | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素组合物在制备抗癌或抗肿瘤药物中的应用及药物 | |
CN108066384A (zh) | 一种具有增强免疫力功能的中药制剂及其制备方法 | |
CN106072569B (zh) | 一种放化疗期间调节病人免疫细胞平衡的特膳食品 | |
CN102805799A (zh) | 一种具有抗恶性肿瘤功效的中药组合物 | |
CN104825817B (zh) | 一种具有抗肿瘤作用的中药制剂 | |
CN108186794A (zh) | 一种治疗恶性肿瘤的中药组合物及其制备方法和应用 | |
CN105477432A (zh) | 一种***的药物组合物 | |
CN107536016B (zh) | 一种保护心脏和促进肝脏健康的营养食品 | |
CN104383283B (zh) | 治疗肠炎、痢疾的口服药物 | |
CN108815301A (zh) | 具有促白细胞生成功效的组合物及其制备方法 | |
CN114515310B (zh) | 一种预防和/或治疗放化疗所致骨髓抑制的药物组合物 | |
CN104857276B (zh) | 一种治疗恶性肿瘤放、化疗后气阴两虚证的中药 | |
CN1100550C (zh) | 一种适用于各种癌症的中药组合物 | |
CN102716465B (zh) | ***的药物组合物及其制备方法 | |
CN105267251A (zh) | 一种含有灰树花(舞茸)多糖、番茄红素和硒的复方制剂及其用途 | |
CN1618461A (zh) | 纳米sod与植物药或其提取物的组合物及其制备方法 | |
CN102716382A (zh) | 一种治疗肺癌的中药组合物及其制备方法 | |
CN1562257A (zh) | 一种预防心脑血管疾病的保健药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171226 |
|
WD01 | Invention patent application deemed withdrawn after publication |